SPK Acquisition Corp. (NASDAQ:SPK) announced in an 8-K this morning that it has terminated its combination agreement with Varian Bio and will instead liquidate on December 29.
The SPAC did not make a required $50,000 contribution to trust on December 10 to extend its transaction deadline and on December 21 gave notice that it would terminate the merger, citing breaches by Varian of one or more of the deal’s terms.
Without the extension payment, SPK was required to liquidate as soon as practicable. It has not yet released an official redemption rate, but it is estimated to have $10.41 per share in its trust.
An earlier extension vote on September 9 saw 79.6% of its shares redeemed, whittling its trust down to about $10.8 million. SPK was only required to maintain more than $5 million in cash available to meet the deal’s conditions, but the combination had already been pending for more than 10 months since its announcement on February 14.
Westport, Connecticut-based Varian Bio is developing two novel therapeutics using aPKCi inhibitors to attempt to impede tumor growth in basal cell carcinomas, the most common cancer type in the world.
This had already been a long road from SPK’s IPO on June 8, 2021 with a nine-month initial clock. This may not mark the end of the story as the transaction stipulates that if the deal was terminated as the result of a breach by either party, that side would owe the other a $2.2 million breakup fee.
Nonetheless, the liquidation is set to occur at the close of business on December 29, with all of SPK’s rights expiring worthless.
With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...
At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...
Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...
Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...
At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...